Figure 6.

Dose response of onabotA duration. Proportion of responders at each visit (subjects with a ≥1-grade Facial Wrinkle Scale [FWS] improvement from baseline at maximum frown), assessed by investigator. Data are from all randomized and treated subjects with a baseline and at least 1 postbaseline efficacy assessment, only in the double-blind phase. * p < 0.05 vs. onabotA 20 U by the Cochran Mantel-Haenszel test stratified by center. ^† Primary time point. Figure reproduced from Joseph et al., 2022 [146] (Creative Commons CC by NC; https://creativecommons.org/licenses/by-nc/4.0/).